ID

DB00240|APRD00783||

名称

Alclometasone

描述

Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

cas号

67452-97-5

唯一标识码

136H45TB7B

状态

solid

组

approved,

指示

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

药效学

Alclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist.

作用机制

The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A₂ inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A₂. Alclometasone initially binds the corticosteroid receptor. This complex migrates to the nucleus where it binds to different glucocorticoid response elements on the DNA. This in turn enhances and represses various genes, especially those involved in inflammatory pathways.

毒性

Symptoms of overdose include suppression of adrenal glands, temporary decrease in white blood cell counts, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), and increased susceptibility to infection.

代谢

Hepatic.

吸收

Topical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.

半衰期

分类

description:This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
direct-parent:21-hydroxysteroids
kingdom:Organic compounds
superclass:Lipids and lipid-like molecules
class:Steroids and steroid derivatives
subclass:Hydroxysteroids
alternative-parent:11-beta-hydroxysteroids
alternative-parent:17-hydroxysteroids
alternative-parent:20-oxosteroids
alternative-parent:3-oxo delta-1,4-steroids
alternative-parent:Alkyl chlorides
alternative-parent:Alpha-hydroxy ketones
alternative-parent:Cyclic alcohols and derivatives
alternative-parent:Cyclic ketones
alternative-parent:Delta-1,4-steroids
alternative-parent:Gluco/mineralocorticoids, progestogins and derivatives
alternative-parent:Halogenated steroids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organochlorides
alternative-parent:Primary alcohols
alternative-parent:Secondary alcohols
alternative-parent:Tertiary alcohols
substituent:11-beta-hydroxysteroid
substituent:11-hydroxysteroid
substituent:17-hydroxysteroid
substituent:20-oxosteroid
substituent:21-hydroxysteroid
substituent:3-oxo-delta-1,4-steroid
substituent:3-oxosteroid
substituent:7-halo-steroid
substituent:Alcohol
substituent:Aliphatic homopolycyclic compound
substituent:Alkyl chloride
substituent:Alkyl halide
substituent:Alpha-hydroxy ketone
substituent:Carbonyl group
substituent:Cyclic alcohol
substituent:Cyclic ketone
substituent:Delta-1,4-steroid
substituent:Halo-steroid
substituent:Hydrocarbon derivative
substituent:Ketone
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organochloride
substituent:Organohalogen compound
substituent:Organooxygen compound
substituent:Oxosteroid
substituent:Pregnane-skeleton
substituent:Primary alcohol
substituent:Progestogin-skeleton
substituent:Secondary alcohol
substituent:Tertiary alcohol

消除途径

种类

Adrenal Cortex Hormones
D000305
Anti-Inflammatory Agents
D000893
Corticosteroid Hormone Receptor Agonists

Corticosteroids
D000305
Corticosteroids, Dermatological Preparations

Corticosteroids, Moderately Potent (Group II)

Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 Substrates

Dermatologicals
D003879
Fused-Ring Compounds
D000072473
Hormones
D006728
Hormones, Hormone Substitutes, and Hormone Antagonists
D006730
Immunosuppressive Agents
D007166
Ophthalmologicals

Pregnadienes
D011245
Pregnadienetriols
D011246
Pregnanes
D011278
Sensory Organs

Steroids
D013256

盐类

DBSALT000893Alclometasone dipropionateS56PQL4N1V66734-13-2DJHCCTTVDRAMEH-DUUJBDRPSA-N521.05520.2227812

蛋白质结合

清除

同义词

language:english; code:; name;(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
language:english; code:; name;7α-Chloro-16α-methylprednisolone
language:english; code:inn; name;Alclometasone

国际品牌

配送量

产品

name:Aclovate
labeller:GlaxoSmithKline
ndc-id:
ndc-product-code:0173-0402
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-10-11
ended-marketing-on:2007-06-29
dosage-form:Ointment
strength:0.05 mg/1
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aclovate
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-0975
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-01
ended-marketing-on:2011-09-30
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076973
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aclovate
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3336
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-01
ended-marketing-on:2011-09-30
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076884
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aclovate
labeller:Glaxosmithkline Inc
ndc-id:
ndc-product-code:0173-0401
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-02-10
ended-marketing-on:2011-02-11
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:NDA018707
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aclovate
labeller:PharmaDerm a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0462-0263
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-01
ended-marketing-on:2015-02-28
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076973
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aclovate
labeller:PharmaDerm a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0462-0264
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-01
ended-marketing-on:2015-02-28
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076884
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2861
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-23
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA079061
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1316
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-07-29
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076730
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:Glenmark Pharmaceuticals Inc., USA
ndc-id:
ndc-product-code:68462-300
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-23
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA079061
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:Glenmark Pharmaceuticals Inc., USA
ndc-id:
ndc-product-code:68462-299
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-30
ended-marketing-on:
dosage-form:Ointment
strength:.5 mg/1g
route:Topical
fda-application-number:ANDA079227
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0168-0263
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-07-12
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076973
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone Dipropionate
labeller:E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0168-0264
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-07-18
ended-marketing-on:
dosage-form:Ointment
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076884
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Alclometasone dipropionate
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1306
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-15
ended-marketing-on:
dosage-form:Cream
strength:0.5 mg/1g
route:Topical
fda-application-number:ANDA076587
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Aclovate
ingredients:Alclometasone
name:Aclovate
ingredients:Alclometasone
name:Aclovate
ingredients:Alclometasone
name:Aclovate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone Dipropionate
ingredients:Alclometasone
name:Alclometasone dipropionate
ingredients:Alclometasone
name:Aclovate
ingredients:Alclometasone
name:Aclovate
ingredients:Alclometasone

包装者

name:Dispensing Solutions
url:http://www.drxdispensing.com
name:E. Fougera and Co.
url:http://www.fougera.com
name:Glenmark Generics Ltd.
url:http://www.glenmark-generics.com
name:Nycomed Inc.
url:http://www.nycomed.com
name:Pharmaderm
url:http://www.pharmaderm.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Taro Pharmaceuticals USA
url:http://www.tarousa.com

生产者

generic:否; url:; name;Nycomed us inc
generic:是; url:; name;Altana inc
generic:是; url:; name;Glenmark generics ltd
generic:是; url:; name;Taro pharmaceuticals usa inc
generic:否; url:; name;Glaxosmithkline

价格

Alclometasone dipro 0.05% crm
1.21(单位：USD）
g
Aclovate 0.05% cream
2.91(单位：USD）
g
Alclometasone Dipropionate 0.05% Ointment 15 gm Tube
16.99(单位：USD）
tube
Alclometasone Dipropionate 0.05% Cream 15 gm Tube
19.81(单位：USD）
tube
Alclometasone Dipropionate 0.05% Ointment 60 gm Tube
39.27(单位：USD）
tube
Alclometasone Dipropionate 0.05% Cream 45 gm Tube
41.31(单位：USD）
tube
Aclovate 0.05% Ointment 15 gm Tube
52.99(单位：USD）
tube
Alclometasone Dipropionate 0.05% Cream 60 gm Tube
52.99(单位：USD）
tube
Aclovate 0.05% Cream 15 gm Tube
54.54(单位：USD）
tube
Aclovate 0.05% Cream 45 gm Tube
81.19(单位：USD）
tube
Aclovate 0.05% Cream 60 gm Tube
103.1(单位：USD）
tube
Aclovate 0.05% Ointment 60 gm Tube
141.1(单位：USD）
tube

受影响的生物体

Humans and other mammals

剂量

form:Cream
route:Topical
strength:0.5 mg/1g
form:Ointment
route:Topical
strength:0.05 mg/1
form:Ointment
route:Topical
strength:0.5 mg/1g
form:Ointment
route:Topical
strength:.5 mg/1g
form:Lotion
route:Topical
strength:0.05 %
form:Lotion
route:Topical
strength:0.1 %
form:Cream
route:Topical
strength:0.1 %
form:Ointment
route:Topical
strength:0.1 %
form:Solution
route:Topical
strength:0.05 %
form:Solution
route:Topical
strength:0.1 %
form:Cream
route:Topical
strength:0.05 %
form:Ointment
route:Topical
strength:0.05 %

atc代码

Corticosteroids, moderately potent (group II)
CORTICOSTEROIDS, PLAIN
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids, plain
ANTIINFLAMMATORY AGENTS
OPHTHALMOLOGICALS
SENSORY ORGANS

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00240.pdf?1265922798

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00240.pdf?1265922738

专利

食物相互作用

药物相互作用

DB00072
Trastuzumab may increase the neutropenic activities of Alclometasone.
DB00864
Tacrolimus may increase the immunosuppressive activities of Alclometasone.
DB00388
The risk or severity of hypertension can be increased when Alclometasone is combined with Phenylephrine.
DB00357
The therapeutic efficacy of Alclometasone can be decreased when used in combination with Aminoglutethimide.
DB00030
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin human.
DB00046
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin lispro.
DB00047
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin glargine.
DB00071
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin pork.
DB00197
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Troglitazone.
DB00222
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glimepiride.
DB00263
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sulfisoxazole.
DB00280
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Disopyramide.
DB00284
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Acarbose.
DB00331
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metformin.
DB00359
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sulfadiazine.
DB00412
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Rosiglitazone.
DB00414
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Acetohexamide.
DB00468
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Quinine.
DB00491
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Miglitol.
DB00672
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Chlorpropamide.
DB00731
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Nateglinide.
DB00738
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Pentamidine.
DB00834
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Mifepristone.
DB00839
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tolazamide.
DB00912
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Repaglinide.
DB00914
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Phenformin.
DB01015
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sulfamethoxazole.
DB01016
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glyburide.
DB01067
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glipizide.
DB01120
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gliclazide.
DB01124
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tolbutamide.
DB01132
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Pioglitazone.
DB01200
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Bromocriptine.
DB01251
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gliquidone.
DB01252
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Mitiglinide.
DB01261
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sitagliptin.
DB01268
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sunitinib.
DB01276
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Exenatide.
DB01277
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Mecasermin.
DB01278
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Pramlintide.
DB01289
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glisoxepide.
DB01306
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin aspart.
DB01307
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin detemir.
DB01309
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin glulisine.
DB01382
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glymidine.
DB01700
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with AICA ribonucleotide.
DB04830
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Buformin.
DB04876
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Vildagliptin.
DB04878
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Voglibose.
DB05115
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with NN344.
DB05819
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with NBI-6024.
DB06011
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with AMG-222.
DB06127
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Bisegliptin.
DB06203
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Alogliptin.
DB06292
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dapagliflozin.
DB06335
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Saxagliptin.
DB06655
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Liraglutide.
DB08382
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gosogliptin.
DB08882
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Linagliptin.
DB08907
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.
DB08962
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Glibornuride.
DB09022
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Benfluorex.
DB09038
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.
DB09043
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Albiglutide.
DB09045
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dulaglutide.
DB09198
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Lobeglitazone.
DB09199
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Netoglitazone.
DB09200
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Rivoglitazone.
DB09201
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Ciglitazone.
DB09265
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Lixisenatide.
DB09456
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin beef.
DB09564
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin degludec.
DB11567
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin peglispro.
DB11568
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin tregopil.
DB11698
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Ipragliflozin.
DB11723
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dutogliptin.
DB11780
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Allicin.
DB11824
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tofogliflozin.
DB11827
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Ertugliflozin.
DB11898
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with 2,4-thiazolidinedione.
DB11950
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Teneligliptin.
DB11992
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Omarigliptin.
DB12268
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Carmegliptin.
DB12412
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gemigliptin.
DB12417
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Anagliptin.
DB12625
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Evogliptin.
DB12713
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sotagliflozin.
DB12781
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Balaglitazone.
DB12935
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Remogliflozin etabonate.
DB13406
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Carbutamide.
DB13446
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Guar gum.
DB13675
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metahexamide.
DB13928
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Semaglutide.
DB14027
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Taspoglutide.
DB14035
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Englitazone.
DB15171
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tirzepatide.
DB15217
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gastric inhibitory polypeptide.
DB00951
The serum concentration of Isoniazid can be decreased when it is combined with Alclometasone.
DB00091
The risk or severity of adverse effects can be increased when Alclometasone is combined with Cyclosporine.
DB00390
The risk or severity of adverse effects can be increased when Alclometasone is combined with Digoxin.
DB00511
The risk or severity of adverse effects can be increased when Alclometasone is combined with Acetyldigitoxin.
DB01078
The risk or severity of adverse effects can be increased when Alclometasone is combined with Deslanoside.
DB01396
The risk or severity of adverse effects can be increased when Alclometasone is combined with Digitoxin.
DB13401
The risk or severity of adverse effects can be increased when Alclometasone is combined with Metildigoxin.
DB13467
The risk or severity of adverse effects can be increased when Alclometasone is combined with Lanatoside C.
DB13537
The risk or severity of adverse effects can be increased when Alclometasone is combined with Gitoformate.
DB13691
The risk or severity of adverse effects can be increased when Alclometasone is combined with Acetyldigoxin.
DB06119
The serum concentration of Alclometasone can be decreased when it is combined with Cenobamate.
DB00252
The serum concentration of Alclometasone can be decreased when it is combined with Phenytoin.
DB01320
The serum concentration of Alclometasone can be decreased when it is combined with Fosphenytoin.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Alclometasone.
DB01601
The serum concentration of Alclometasone can be increased when it is combined with Lopinavir.
DB00503
The serum concentration of Alclometasone can be increased when it is combined with Ritonavir.
DB00232
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Methyclothiazide.
DB00436
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Bendroflumethiazide.
DB00562
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Benzthiazide.
DB00606
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Cyclothiazide.
DB00774
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Hydroflumethiazide.
DB00880
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Chlorothiazide.
DB00999
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Hydrochlorothiazide.
DB01021
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Trichlormethiazide.
DB01324
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Polythiazide.
DB13430
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Mebutizide.
DB13532
The risk or severity of electrolyte imbalance can be increased when Alclometasone is combined with Cyclopenthiazide.
DB00502
The serum concentration of Haloperidol can be increased when it is combined with Alclometasone.
DB11652
The metabolism of Tucatinib can be decreased when combined with Alclometasone.
DB12530
The risk or severity of infection can be increased when Alclometasone is combined with Inebilizumab.
DB11932
The serum concentration of Alclometasone can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Alclometasone can be decreased when it is combined with Satralizumab.

序列

实验性质

Water Solubility
Insoluble

logP
2.7

外部标识符

resource：ChEBI
identifier：53776
resource：PubChem Compound
identifier：5311000
resource：PubChem Substance
identifier：46508296
resource：KEGG Drug
identifier：D07116
resource：ChemSpider
identifier：4470541
resource：PharmGKB
identifier：PA164747650
resource：Therapeutic Targets Database
identifier：DAP000415
resource：Wikipedia
identifier：Alclometasone
resource：ChEMBL
identifier：CHEMBL1201361
resource：ZINC
identifier：ZINC000030691420
resource：RxCUI
identifier：108088

外部链接

RxList
http://www.rxlist.com/cgi/generic3/alclometasone.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/acl1005.shtml
Drugs.com
http://www.drugs.com/cdi/alclometasone-cream.html

路径

目标

id:BE0000794
name:Glucocorticoid receptor
organism:Humans
action:agonist
Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62.
Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6.
known-action:yes
name:Glucocorticoid receptor
general-function:Zinc ion binding
specific-function:Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.
gene-name:NR3C1
locus:5q31.3
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:6.31
molecular-weight:85658.57
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:7978GenAtlasNR3C1GenBank Gene DatabaseX03225GenBank Protein Database31680IUPHAR625Guide to Pharmacology625UniProtKBP04150UniProt AccessionGCR_HUMAN
synonyms:GRGRLNuclear receptor subfamily 3 group C member 1
amino-acid-sequence:>lcl|BSEQ0001584|Glucocorticoid receptor MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK
gene-sequence:>lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1) ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA
pfams:PF00104Hormone_recepPF00105zf-C4PF02155GCR
go-classifiers:componentcytoplasmcomponentmitochondrial matrixcomponentnucleoplasmcomponentnucleusfunctionglucocorticoid receptor activityfunctionglucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activityfunctionRNA polymerase II core promoter proximal region sequence-specific DNA bindingfunctionsteroid bindingfunctionsteroid hormone bindingfunctiontranscription factor activity, sequence-specific DNA bindingfunctiontranscriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingfunctionzinc ion bindingprocesscellular response to steroid hormone stimulusprocesschromatin modificationprocessgene expressionprocesspositive regulation of transcription from RNA polymerase II promoterprocessregulation of transcription, DNA-templatedprocesssignal transductionprocesstranscription from RNA polymerase II promoterprocesstranscription initiation from RNA polymerase II promoterprocesstranscription, DNA-templated

酶

BE0002638Cytochrome P450 3A4HumanssubstrateT306978-0-803-669468Vallerand A. and Sanoski C. (2017). David's Canadian Drug Guide for Nurses (16th ed.). FA Davis Company.noCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic process

载体

BE0000209Corticosteroid-binding globulinHumansbinderA171317139284Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.A171517016423Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.A911752352Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.unknownCorticosteroid-binding globulinSteroid bindingMajor transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.SERPINA614q32.1Secreted1-225.9445140.4914HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:1540GenAtlasSERPINA6GenBank Gene DatabaseJ02943GenBank Protein Database179971UniProtKBP08185UniProt AccessionCBG_HUMANCBGSerpin A6Transcortin>lcl|BSEQ0016035|Corticosteroid-binding globulin MPLLLYTCLLWLPTSGLWTVQAMDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPK KNIFISPVSISMALAMLSLGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSD TSLEMTMGNALFLDGSLELLESFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQG KIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENFYVDETTVVKVPMMLQSSTI SYLHDSELPCQLVQMNYVGNGTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLY IPKVTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGVDT AGSTGVTLNLTSKPIILRFNQPFIIMIFDHFTWSSLFLARVMNPV>lcl|BSEQ0016036|Corticosteroid-binding globulin (SERPINA6) ATGCCACTCCTCCTGTACACCTGTCTTCTCTGGCTGCCCACCAGCGGCCTCTGGACCGTC CAGGCCATGGATCCTAACGCTGCTTATGTGAACATGAGTAACCATCACCGGGGCCTGGCT TCAGCCAACGTTGACTTTGCCTTCAGCCTGTATAAGCACCTAGTGGCCTTGAGTCCCAAA AAGAACATTTTCATCTCCCCTGTGAGCATCTCCATGGCCTTAGCTATGCTGTCCCTGGGC ACCTGTGGCCACACACGGGCCCAGCTTCTCCAGGGCCTGGGTTTCAACCTCACTGAGAGG TCTGAGACTGAGATCCACCAGGGTTTCCAGCACCTGCACCAACTCTTTGCAAAGTCAGAC ACCAGCTTAGAAATGACCATGGGCAATGCCTTGTTTCTTGATGGCAGCCTGGAGTTGCTG GAGTCATTCTCAGCAGACATCAAGCACTACTATGAGTCAGAGGTCTTGGCTATGAATTTC CAGGACTGGGCAACAGCCAGCAGACAGATCAACAGCTATGTCAAGAATAAGACACAGGGG AAAATTGTCGACTTGTTTTCAGGGCTGGATAGCCCAGCCATCCTCGTCCTGGTCAACTAT ATCTTCTTCAAAGGCACATGGACACAGCCCTTTGACCTGGCAAGCACCAGGGAGGAGAAC TTCTATGTGGACGAGACAACTGTGGTGAAGGTGCCCATGATGTTGCAGTCGAGCACCATC AGTTACCTTCATGACGCGGAGCTCCCCTGCCAGCTGGTGCAGATGAACTACGTGGGCAAT GGGACTGTCTTCTTCATCCTTCCGGACAAGGGGAAGATGAACACAGTCATCGCTGCACTG AGCCGGGACACGATTAACAGGTGGTCCGCAGGCCTGACCAGCAGCCAGGTGGACCTGTAC ATTCCAAAGGTCACCATCTCTGGAGTCTATGACCTCGGAGATGTGCTGGAGGAAATGGGC ATTGCAGACTTGTTCACCAACCAGGCAAATTTCTCACGCATCACCCAGGACGCCCAGCTG AAGTCATCAAAGGTGGTCCATAAAGCTGTGCTGCAACTCAATGAGGAGGGTGTGGACACA GCTGGCTCCACTGGGGTCACCCTAAACCTGACGTCCAAGCCTATCATCTTGCGTTTCAAC CAGCCCTTCATCATCATGATCTTCGACCACTTCACCTGGAGCAGCCTTTTCCTGGCGAGG GTTATGAACCCAGTGTAAPF00079Serpincomponentextracellular exosomecomponentextracellular spacefunctionserine-type endopeptidase inhibitor activityfunctionsteroid bindingprocessglucocorticoid metabolic processprocessnegative regulation of endopeptidase activityprocesstransport

运输工具

药物反应

效应

不良反应